Last update 04 Oct 2025

ATB-301

Overview

Basic Info

Drug Type
ASO
Synonyms
aldesleukin + TASO-001, aldesleukin + trabedersen, recombinant IL-2 + TGF-beta 2 targeting anti-sense oligonucleotide
+ [2]
Target
TGF-β2
Action
inhibitors
Mechanism
TGF-β2 inhibitors(Transforming growth factor beta 2 inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Pancreatic CancerRenal Cell CarcinomaMetastatic Solid Tumor+ [1]
Inactive Indication-
Originator Organization
Autotelic Bio Co. Ltd.
Active Organization
Autotelic Bio Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
login
or
view full example data
Boost your research with our RNA technology data.

Related

1
Clinical Trials associated with ATB-301
NCT04862767
/ CompletedPhase 1
Multi-center, Open Label, Phase Ib Clinical Trial to Evaluate Safety, Tolerance and Efficacy of TASO(TGF-β2 Targeting Anti-sense Oligonucleotide)-001 in Combination With Recombinant Interleukin-2 in Advanced or Metastatic Solid Tumor
100 Clinical Results associated with ATB-301
Login to view more data
100 Translational Medicine associated with ATB-301
Login to view more data
100 Patents (Medical) associated with ATB-301
Login to view more data
100 Deals associated with ATB-301
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 1
South Korea
Autotelic Bio Co. Ltd.
11 May 2023
Renal Cell CarcinomaPhase 1
South Korea
Autotelic Bio Co. Ltd.
11 May 2023
Metastatic Solid TumorPhase 1
United States
Autotelic Bio Co. Ltd.
09 Mar 2021
Solid tumorPhase 1
United States
Autotelic Bio Co. Ltd.
09 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASCO2011
Phase 1/2
Melanoma | Colorectal Cancer | Pancreatic Cancer
33
vvfnsqpfsp(tuszwdytke) = wtozjflqgl cvugwchaav (xwsvcxfary )
-
20 May 2011
ASCO2010
Phase 1/2
Neoplasms
33
frzxyodxtm(kbekbenfbd) = The only expected adverse reaction identified was nonserious, transient thrombocytopenia sulboofher (ddluwihqbs )
View more
-
20 May 2010
ASCO2009
Phase 1/2
Melanoma | Colorectal Cancer | Pancreatic Cancer
33
msxivxeqnv(swkhuqxagp) = igedzdzpxy korqpycvyt (buzrvwiztr )
-
20 May 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free